Understanding these factors is crucial for identifying patient groups that may benefit from a pegylated interferon alpha (Peg-IFN-α) induced “functional cure” for hepatitis B, as well as for optimizing strategies to achieve and sustain HBsAg loss. This evidence concerns the gene IFNA1 and hepatitis B virus infection.